European Urology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 1, 2024
While
prostate
cancer
(PCa)
incidence
and
mortality
rates
continue
to
rise,
early
detection
of
PCa
remains
highly
controversial,
the
research
landscape
is
rapidly
evolving.
Existing
systematic
reviews
(SRs)
meta-analyses
(MAs)
provide
valuable
insights,
but
often
focus
on
single
aspects
detection,
hindering
a
comprehensive
understanding
topic.
We
aim
fill
this
gap
by
providing
SR
contemporary
SRs
covering
different
in
European
Union
(EU)
UK.
Theranostics,
Journal Year:
2024,
Volume and Issue:
14(5), P. 1829 - 1840
Published: Jan. 1, 2024
Rationale:
Evaluation
of
alternative
radionuclides
for
use
in
prostate-specific
membrane
antigen
(PSMA)-targeted
radioligand
therapy
(RLT)
is
currently
focusing
on
161
Tb,
which
may
provide
advantages
by
emitting
additional
Auger
and
conversion
electrons.In
this
pilot
study,
we
present
preliminary
dosimetry
data
[
Tb]Tb-PSMA-617
RLT
a
direct
comparison
with
177
Lu]Lu-PSMA-617.Method:
Six
patients
metastatic
castration-resistant
prostate
cancer
(mCRPC)
underwent
treatment
Lu]Lu-PSMA-617
subsequently
-after
inadequate
response
-with
Tb]Tb-PSMA-617.Whole-body
planar
SPECT
imaging-based
organs
at
risk
(kidneys
salivary
glands)
tumor
lesions
were
calculated
using
IDAC
Lu
OLINDA/EXM
Tb.The
therapeutic
index
(TI)
mean
tumor-absorbed
doses
over
relevant
was
calculated.Results:
Mean
absorbed
to
PSMA-RLT
slightly
higher
compared
(kidneys:
0.643
±
0.247
vs.
0.545
0.231
Gy/GBq,
factor
1.18;
parotid
gland:
0.367
0.198
0.329
0.180
1.10),
but
markedly
regarding
(6.10
6.59
vs
2.59
3.30
2.40,
p
<
0.001).Consequently,
the
TI
both,
kidneys
(11.54
9.74
5.28
5.13,
=
0.002)
gland
(16.77
13.10
12.51
18.09,
0.008).
Conclusion:In
intra-individual
head-to-head
delivered
resulted
superior
Lu]Lu-PSMA-617.This
support
Tb
as
promising
radionuclide
mCRPC.
Molecular Biomedicine,
Journal Year:
2025,
Volume and Issue:
6(1)
Published: Jan. 6, 2025
Cancer
remains
a
leading
cause
of
mortality
globally
and
major
health
burden,
with
chemotherapy
often
serving
as
the
primary
therapeutic
option
for
patients
advanced-stage
disease,
partially
compensating
limitations
non-curative
treatments.
However,
emergence
resistance
significantly
limits
its
efficacy,
posing
clinical
challenge.
Moreover,
heterogeneity
mechanisms
across
cancer
types
complicates
development
universally
effective
diagnostic
approaches.
Understanding
molecular
chemoresistance
identifying
strategies
to
overcome
it
are
current
research
focal
points.
This
review
provides
comprehensive
analysis
key
underlying
resistance,
including
drug
efflux,
enhanced
DNA
damage
repair
(DDR),
apoptosis
evasion,
epigenetic
modifications,
altered
intracellular
metabolism,
role
stem
cells
(CSCs).
We
also
examine
specific
causes
in
highlight
various
targets
involved
resistance.
Finally,
we
discuss
aiming
at
overcoming
such
combination
therapies,
targeted
treatments,
novel
delivery
systems,
while
proposing
future
directions
this
evolving
field.
By
addressing
these
barriers,
lays
foundation
more
therapies
aimed
mitigating
Frontiers in Pharmacology,
Journal Year:
2025,
Volume and Issue:
15
Published: Jan. 9, 2025
The
natural
killer
(NK)
activity
of
peripheral
blood
mononuclear
cells
(PBMCs)
is
a
crucial
defense
against
the
onset
and
spread
cancer.
Studies
have
shown
that
patients
with
reduced
NK
are
more
susceptible
to
cancer,
tends
decrease
due
cancer-induced
immune
suppression.
Enhancing
cytotoxicity
PBMCs
remains
significant
task
in
cancer
research.
This
study
investigates
potential
urolithin
A,
polyphenolic
metabolite
produced
by
gut
microbiota,
enhance
prostate
healthy
subjects.
We
investigated
possible
role
aryl
hydrocarbon
receptor
(AhR)
this
capability
A.
analyzed
ability
preincubated
AhR
agonist
or
antagonist
kill
K562
(human
chronic
myelogenous
leukemia)
target
cells.
Our
results
demonstrate
A
enhances
dose-dependent
manner.
Specifically,
at
concentration
10
μM,
increased
from
an
average
23%
(95%
CI,
7%-38%).
In
addition,
modulates
level
cytokine
production
PBMCs,
decreasing
fractalkine,
IL-8,
MCP-3.
An
(CH223191,
1
μM)
also
activity,
while
(β-naphthoflavone,
did
not
increase
partially
inhibited
A-induced
enhancement.
Urolithin
increases
subjects,
may
be
involved
Frontiers in Cell and Developmental Biology,
Journal Year:
2024,
Volume and Issue:
12
Published: March 19, 2024
Introduction:
Despite
the
abundance
of
research
indicating
participation
immune
cells
in
prostate
cancer
development,
establishing
a
definitive
cause-and-effect
relationship
has
proven
to
be
difficult
undertaking.
Methods:
This
study
employs
Mendelian
randomization
(MR),
leveraging
genetic
variables
related
from
publicly
available
genome-wide
association
studies
(GWAS),
investigate
this
association.
The
primary
analytical
method
used
is
inverse
variance
weighting
(IVW)
analysis.
Comprehensive
sensitivity
analyses
were
conducted
assess
heterogeneity
and
horizontal
pleiotropy
results.
Results:
identifies
four
cell
traits
as
causally
contributing
risk,
including
CD127-
CD8+
T
%CD8+
(OR
=
1.0042,
95%CI:1.0011–1.0073,
p
0.0077),
CD45RA
on
CD39+
resting
CD4
regulatory
1.0029,
95%CI:1.0008–1.0050,
0.0065),
CD62L−
Dendritic
Cell
Absolute
Count
1.0016;
95%CI:1.0005–1.0026;
0.0039),
CX3CR1
CD14+
CD16−
monocyte
1.0024,
95%CI:1.0007–1.0040,
0.0060).
Additionally,
two
are
identified
protective
factors:
0.9975,
95%CI:0.9958–0.9992,
0.0047),
FSC-A
plasmacytoid
0.9983,
95%CI:0.9970–0.9995,
0.0070).
Sensitivity
indicated
no
pleiotropy.
Discussion:
Our
MR
provide
evidence
for
causal
between
cancer,
holding
implications
clinical
diagnosis
treatment.
Cell Death Discovery,
Journal Year:
2024,
Volume and Issue:
10(1)
Published: April 11, 2024
Abstract
FOXA1
(Forkhead
Box
A1)
and
FOXA2
A2)
serve
as
pioneering
transcription
factors
that
build
gene
expression
capacity
play
a
central
role
in
biological
processes,
including
organogenesis
differentiation,
glycolipid
metabolism,
proliferation,
migration
invasion,
drug
resistance.
Notably,
may
exert
antagonistic,
synergistic,
or
complementary
effects
the
aforementioned
processes.
This
article
focuses
on
molecular
mechanisms
clinical
relevance
of
steroid
hormone-induced
malignancies
highlights
potential
strategies
for
targeting
cancer
therapy.
Furthermore,
describes
prospect
upstream
regulators
FOXA1/FOXA2
to
regulate
its
therapy
because
untargetability
FOXA1/FOXA2.
Frontiers in Endocrinology,
Journal Year:
2024,
Volume and Issue:
15
Published: Feb. 9, 2024
Background
There
is
still
limited
research
on
the
association
between
immune
cells
and
risk
of
prostate
cancer.
Further
investigations
are
warranted
to
comprehend
intricate
associations
at
play.
Methods
We
used
a
bidirectional
two-sample
Mendelian
randomization
(MR)
analysis
investigate
causal
relationship
cell
phenotypes
The
summary
data
for
was
derived
from
study
cohort,
including
3,757
individuals
Sardinia
with
731
phenotypes.
cancer
were
obtained
UK
Biobank
database.
Sensitivity
analyses
conducted,
combination
MR-Egger
MR-Presso
assess
horizontal
pleiotropy.
Cochran’s
Q
test
employed
evaluate
heterogeneity,
results
subjected
FDR
correction.
Results
Our
identified
two
significantly
associated
cancer,
namely
CD25
naive-mature
B
(OR
=
0.998,
95%
CI,
0.997-0.999,
P
2.33E-05,
0.017)
HLA
DR
CD14-
CD16-
1.001,
1.000-1.002,
8.01E-05,
0.03).
When
adjusting
0.2,
we
additionally
found
six
influencing
incidence
These
include
FSC-A
1.002,
1.001-1.002,
7.77E-04,
0.133),
plasmacytoid
dendritic
1.000-1.001,
0.001,
CD14+
monocyte
%
monocytes
1.001-1.003,
HVEM
effector
memory
CD4+
T
0.002,
0.169),
which
positively
correlated
Conversely,
IgD+
0.169)
Monocytic
Myeloid-Derived
Suppressor
Cells
AC
0.999,
0.999-1.000,
0.17)
negatively
Conclusion
This
has
revealed
relationships
supplying
novel
insights
that
might
aid
in
identifying
potential
therapeutic
targets
